

Ribociclib MONALEESA-7

### PRELIMINARY SCORE

**CURATIVE**




**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Delayed deterioration in global QoL

**Serious and disabling adverse effects**



**Other adjustments**



Ribociclib MONALEESA-7

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.  
 Experimental Arm: Ribociclib + Endocrine therapy  
 Control Arm: Placebo + endocrine therapy



